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Edited by Robert BaroukiAbstract Low-molecular-weight organic chromium complexes
such as chromium picolinate are often used as dietary supple-
ments to improve insulin sensitivity and to correct dyslipidemia.
However, toxicity associated with such chromium compounds
has compromised their therapeutic value. The aim of this study
was to evaluate the impact of a newly synthesized complex of
chromium with phenylalanine, Cr(pa)3 on insulin-signaling and
glucose tolerance. Cr(pa)3 was synthesized by chelating chro-
mium(III) with D-phenylalanine ligand in aqueous solution. In
mouse 3T3-adipocytes, Cr(pa)3 augmented insulin-stimulated
glucose-uptake as assessed by a radioactive-glucose uptake as-
say. At the molecular level, Cr(pa)3 enhanced insulin-stimulated
phosphorylation of Akt in a time- and concentration-dependent
manner without altering the phosphorylation of insulin receptor.
Oral treatment with Cr(pa)3 (150 lg/kg/d, for six weeks) in ob/
ob(+/+) obese mice signiﬁcantly alleviated glucose tolerance
compared with untreated obese mice. Unlike chromium picoli-
nate, Cr(pa)3 does not cleave DNA under physiological reducing
conditions. Collectively, these data suggest that Cr(pa)3 may
represent a novel, less-toxic chromium supplement with potential
therapeutic value to improve insulin sensitivity and glycemic con-
trol in type II diabetes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Insulin resistance is concomitant with type II diabetes,
obesity, hypertension, and other features of the metabolic
syndrome [1]. It is the major risk factor for cardiovascular
diseases and one of the leading causes of mortality and mor-
bidity. Proper management of insulin resistance has been
shown to play a pivotal role in the reduced risk for cardio-
vascular diseases. However, compounds which improve the*Corresponding author.
E-mail address: sreejay@uwyo.edu (N. Sreejayan).
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doi:10.1016/j.febslet.2005.01.049sensitivity of insulin are somewhat limited. These com-
pounds such as pioglitazone augment the action of insulin
by increasing insulin sensitivity and may be of beneﬁt for
the long-term treatment for type II diabetes. One such com-
pound is the mineral chromium. Chromium is thought to
play a key role in normal carbohydrate metabolism by
potentiating the action of insulin, leading to increased insu-
lin sensitivity in type II diabetes and obesity [2]. Dietary
deﬁciency of chromium has been shown to increase the risk
of developing diabetes [3]. Clinical trials have demonstrated
that supplementation with chromium chloride or chromium
picolinate can lower blood glucose levels in diabetic patients
[4].
Better bioavailability of low-molecular-weight organic
chromium complexes as compared to chromium salts (2–
5% versus 0.5–2%) has led to the development of low-molec-
ular-weight organic complexes of chromium as therapeutic
agents to counter the diminished insulin eﬀect under type
II diabetes [5]. Emerging evidence has shown that the
biologically active form of chromium is a chromium-oligo-
peptide complex, which further justiﬁes the use of organic-
chromium-complexes as biomimetic chromium supplements
[6]. The chromium complex of picolinic acid, the most pop-
ularly used dietary supplement has been shown to modulate
intracellular pathways of glucose metabolism and improve
comorbidities associated with insulin resistance in several
animal and human studies [7,8]. However, recent reports
have indicated that the picolinate ligand may shift the redox
potential of chromium in the complex such that it can be re-
duced by biological reductants to generate hydroxyl radicals
causing deleterious DNA mutations [9,10]. The pro-oxidant
nature of chromium picolinate, greatly limited its therapeutic
applications and prompted us to seek other safe synthetic
chromium complex with a natural amino acid ligand [10].
The objective of this study was therefore to evaluate the
ability of a newly synthesized complex of chromium with
the amino acid D-phenylalanine, Cr(pa)3, on insulin-signaling
transduction and glucose uptake in 3T3-adipoctes, and glu-
cose clearance in a ob/ob(+/+) mouse model of insulin resis-
tance/type II diabetes. It was also of interest to test the
hydroxyl radicals generating capacity and DNA damage of
Cr(pa)3 since such is the case for the toxicity of chromium
picolinate.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Insulin Receptor beta polyclonal antibody was obtained from San-
ta Cruz Biotechnology (Santa Cruz, CA). All other antibodies used
in this study were from Cell Signaling Technology Inc (Beverly,
MA). Dulbeccos Modiﬁed Eagle Medium (DMEM), penicillin-strep-
tomycin liquid, insulin/transferrin/selenous acid (ITS), fetal bovine
serum (FBS), newborn calf serum (CS) were from Invitrogen Corpo-
ration (Carlsbad, CA). Micro BCA protein assay kit was from Pierce
Chemical (Rockford, IL). pUC19 DNA was obtained from New
England Biolabs (Beverly, MA). Chromium picolinate was a kind
gift from Dr. J.B. Vincent (The University of Alabama, Tuscaloosa,
AL). All other chemicals were from Sigma–Aldrich Chemical Co (St.
Louis, MO). Doubly deionized water was used to prepare stock solu-
tions of chromium complex for all experiments unless otherwise
indicated.2.2. Synthesis and characterization of Cr(pa)3
Aqueous solutions of CrCl3 Æ 6H2O (2.6 g; 10 mmol in 50 ml water)
and D-phenylalanine (4.8 g, 30 mmol in 50 ml water) were mixed at
80 C and reﬂuxed for 4 h. The homogeneous green reaction mixture
was freeze–dried. The greenish-violet solid obtained was washed with
acetone and dried in air oven. Yield: 81%, m.p. > 300 C. Found: C,
47.84; H, 5.60; N, 5.92. The stoichiometry Cr(C27H30N3O6) Æ 3HCl Æ
2H2O requires C, 47.00; H, 5.40; N, 6.09. The ESMS of the complex
in methanolic solution registers signals at 545.1 and 165.9 representing,
respectively, the tris chelate and the deprotonated ligand. Formation
of the complex was associated with mC‚O (1563 cm
1) and mN–H
(3535 cm1) shifts in the IR-spectrum by about 40 and 30 cm1,
respectively. The broadening of the moderately sharp absorption band
in the free ligand (2900–3100 cm1) to about 600 cm1 may be attrib-
uted to the reorganization in intramolecular hydrogen bonding after
chelation. New absorption bands in the far IR region around 370
and 310 cm1 can be assigned to the Cr–O and Cr–N bonds. The
UV–Vis spectrum of the methanolic solution of the complex registered
bands at 15 673 cm1 (m1) and 22 075 cm
1 (m2). The complex being
green in color, the above two bands are due to the absorption in yellow
and blue parts of the spectrum. These absorptions are due to the spin
allowed transitions 4T2g‹ 4A2g (m1) and 4T1g(F)‹ 4A2g (m2). The third
band m3 overlaps with UV absorption of the ligand. These observations
suggest a hexa-coordinate environment around chromium (III). The
pH of the aqueous solution of the complex is 4.7 and the presence of
chloride demonstrates the presence of HCl in the lattice. Based on
the stoichiometry, elemental analysis and spectral studies, the prod-
uct obtained is a complex containing a 1:3 ratio of chromium to
phenylalanine.2.3. Cell culture and diﬀerentiation
The 3T3-L1-pre-adipocytes were obtained from the American Type
Culture Collection and were propagated at 37 C in DMEM with 10%
newborn calf serum plus 50 U/ml penicillin and 50 lg/ml streptomycin
in an incubator under a humidiﬁed atmosphere of 5% CO2/95% air.
Induction of diﬀerentiation was done one day post-conﬂuence. Cells
were maintained in diﬀerentiation medium of the following composi-
tion: DMEM, 10% FBS, 0.2 lg/ml dexamethasone, 0.5 mM 1-isobu-
tyl-3-methylxanthine (IBMX) and ITS for three days. At day 3, the
dexamethasone and IBMX were removed with ITS remaining on the
cells for an additional two days. Diﬀerentiation was allowed to con-
tinue in DMEM supplemented with 10% FBS, ITS and the adipocytes
were used between day 9 and 14 post-induction. Prior to the cellular
assays, cells were serum starved by overnight incubation in DMEM
(containing 0.2% serum).
2.4. Gel electrophoresis and Western blotting
Cells were lysed in RIPA buﬀer (150 mM NaCl, 0.25% sodium des-
oxycholate, 1% NP-40, 1 mM EDTA and 50 mM Tris, pH 7.2) con-
taining 2 mM sodium vanadate, 1 lM PMSF, 1 lM sodium ﬂuoride,
1 lg/ml aprotinin, 1 lg/ml leupeptin, and 1 lM pepstatin and soni-
cated to reduce the sample viscosity. The lysate was centrifuged at
15 000 · g for 15 min at 4 C and the protein concentration in the
supernatant was determined by the bicinchoninic acid method. Equiv-
alent amounts of proteins were boiled in Laemmli sample buﬀer. Pro-teins 10–20 lg were separated on 7.5–10% polyacrylamide gel, and
electrophoretically transferred to a nitrocellulose membrane. The
membranes were incubated at for 1 h at room temperature in blocking
buﬀer (5% w/v non-fat dry milk in tris buﬀered saline containing 0.1%
Tween 20). Membranes were incubated in appropriate phospho-spe-
ciﬁc primary antibody for insulin receptor beta or Akt at 1:2500 dilu-
tions in the blocking buﬀer followed by incubation with horseradish
peroxidase-coupled secondary antibodies with appropriate speciﬁcity.
Immunoreactive bands were visualized using enhanced chemilumines-
cence reagents (Cell Signaling Technology, Inc, Beverly, MA). Blots
were then stripped and re-probed with antibodies directed against insu-
lin receptor b and Akt.2.5. Animals and treatment protocol
All animal treatment procedures described in this study were ap-
proved by the animal Care and Use Committee at University of Wyo-
ming (Laramie, WY). Homozygous B6.V-lep ob>/J male mice
purchased from the Jackson Laboratory (Bar Harbor, ME) at age 5
week were divided randomly into two weight-matched groups, marked
as ob/ob(+/+) control and ob/ob(+/+) treatment (n = 10). Number, age
and weight matched normal C57 mice were used as lean control. All of
these animals were maintained on conventional laboratory diet under
well-controlled conditions of temperature (22 ± 2 C), humidity
(55 ± 5%) and 12 h/12 h light–dark cycle and had ad libitum access
to water and standard rodent chow. Rodent diet and tap water were
consumed by mice ad libitum. Cr(pa)3 was provided in the drinking
water and, on the basis of water intake, was administered to provide
an intake of about 150 lg/kg/day corresponding to about 10–15 lg ele-
mental Cr/kg/day for ob/ob(+/+) and lean treatment groups. The dos-
age of chromium used was based on earlier animal studies reported
with chromium picolinate [11].2.6. Intraperitoneal glucose tolerance test
At the end of the treatment schedule, mice were subjected to the
intraperitoneal glucose tolerance test (IPGTT) as described previously
[12]. Brieﬂy, the mice were fasted for 12 h and then given intraperito-
neal injection of glucose (2 g/kg body weight). Glucose levels were
determined in blood drops obtained by clipping the tail of the mice
immediately before glucose challenge, as well as at 15, 60 and
120 min thereafter. Serum glucose levels were determined using
ACCU-CHEK Advantage Glucose Analyzer (Roche Diagnostics
Corporation, IN). Results of IPGTT are also expressed as integrated
areas under the curves (AUC) over 120 min for glucose calculated by
using the WinNonlin software (Pharsight Corporation, Mountain
View, CA).2.7. Assay for generation of hydroxyl radicals
The potential of chromium compounds to generate hydroxyl rad-
icals in vitro was assessed by the method of Gutteridge et al. [13].
Brieﬂy, a reaction mixture containing either chromium picolinate
or Cr(pa)3, 2-deoxyribose (4 mM), ascorbic acid (100 lM) and
hydrogen peroxide (100 lM) in potassium phosphate buﬀer (pH
7.4, 10 mM) was incubated at 37 C for 30 min. An aliquot of the
mixture was treated with 1% (w/v) thiobarbituric acid and 2.8%
(w/v) trichloroacetic acid and heated at 90 C for 10 min, rapidly
cooled and the amount of chromogen formed in the sample was
measured by its absorption at 532 nm. Ferric-EDTA (100 lM) was
used as a positive control.2.8. DNA cleavage reactions
DNA cleavage-stimulated by chromium compounds was assessed as
described previously [14]. All solutions were prepared using Chelex-100
treated water to remove any traces of metal ions. Aliquots of pUC19
(about 40 lM in base pairs in 5 mM Tris, 500 lM EDTA buﬀer, pH
8.0) were mixed with ascorbic acid (5 mM) in the presence of the test
compounds in phosphate buﬀered saline (pH 7.4), to give a ﬁnal vol-
ume of 15 ll. Reactions were allowed to proceed 60 min followed by
quenching with 2 ll of nucleic acid sample loading buﬀer. The mixtures
were loaded directly onto a 1% agarose gel pre-stained by ethidium
bromide and electrophoresed at 60 V. The gels were photographed
on a UV transilluminator.
Fig. 1. Cr(pa)3 improves insulin-stimulated glucose uptake in cultured
mouse 3T3-adipocytes. Cells were treated with insulin (6 nM) and in
the presence or absence of Cr(pa)3 (5 or 25 lM) for 10 days
accompanying the procedure of diﬀerentiation of the cells. Uptake of
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Glucose uptake activity was analyzed by measuring the uptake of 2-
deoxy-D-[3H] glucose as described previously [15]. Brieﬂy, conﬂuent
3T3-L1 adipocytes grown in 6-well plates were washed twice with ser-
um-free DMEM and incubated with 2 ml of the same medium at 37 C
for 2 h. The cells were washed 3 times with Krebs-Ringer-HEPES
(KRH) buﬀer and incubated with 2 ml KRH buﬀer at 37 C for
30 min. Insulin (6 nM) and/or Cr(pa)3 (0–25 lM) were then added to
adipocytes accompanying the procedure of diﬀerentiation. Glucose up-
take was initiated by the addition of 0.1 ml KRH buﬀer and 2-deoxy-
D-[3H] glucose (0.2 lCi/ml) and 5 mM glucose as ﬁnal concentrations.
Glucose uptake was terminated by washing the cells three times with
cold PBS. The cells were lysed overnight with 1 ml 0.5 M NaOH and
0.1% SDS (w/v). The radioactivity retained by the cell lysates was
determined by a scintillation counter (Beckmann LC 6000IC) and nor-
malized to protein amount measured with a Micro BCA Protein Assay
Kit (Pierce Chemical, Rockford, IL).
2.10. Data analysis
Data are expressed as means ± S.E.M. and statistically evaluated
using Students paired t test using Sigma Plot statistical software (Jan-
del Scientiﬁc, San Rafael, CA). A P value of less than 0.05 was consid-
ered to be statistically signiﬁcant.radiolabeled glucose in the cells was measured as explained in Section
2. Results are means ± S.E.M. Preincubation with Cr(pa)3 signiﬁcantly
enhanced insulin-stimulated cellular glucose uptake (*P < 0.05, n = 3)
as compared to insulin-stimulated glucose uptake in untreated cells.3. Results
3.1. Synthesis and characterization of Cr(pa)3
A multi-step synthesis of chromium complexes of L-phenyl-
alanine and D,L-phenylalanine using aqua(isothiocyanato)bis-
(L-phenylalaninato)chromium and D,L- or L-phenylalanine as
starting material has been reported previously [16]. In contrast,
a simpler, single step reaction was used in this study to synthe-
size the complex of chromium(III) with D-phenylalanine in
aqueous solution. The synthetic protocol used in the paper
was closer to that reported by Abdel-Monem et al. [17] for
the synthesis of similar complexes of chromium with L-amino
acids. Elemental analysis and spectral studies indicate that the
ratio of chromium to D-phenylalanine in the complex is 1:3.3.2. Cr(pa)3 enhances insulin-stimulated glucose uptake in
adipocytes
Chromium has been shown to improve insulin-stimulated
glucose uptake in cultured cells sensitive to insulin [18]. The
eﬀect of Cr(pa)3 on insulin-stimulated glucose-uptake in 3T3-
adipocytes, an insulin-sensitive cell line, was investigated using
the 2-deoxy-D-glucose-3H uptake assay. As shown in Fig. 1,
incubation with insulin (6 nM) during the course of diﬀerenti-
ation of the adipocytes, stimulated a fourfold increase in glu-
cose uptake by adipocytes, consistent with a previous report
[15]. Pre-incubation of the cells with Cr(pa)3 (5 and 25 lM) sig-
niﬁcantly augmented insulin-stimulated glucose uptake in 3T3-
adipocytes. In the absence of insulin, Cr(pa)3 did not have any
eﬀect on basal glucose uptake (data not shown). These results
demonstrate that Cr(pa)3 potentiates insulin-stimulated but
not basal glucose uptake.3.3. Cr(pa)3 does not alter insulin-stimulated tyrosine
phosphorylation of insulin receptor beta (IRb)
Insulin is thought to initiate its signaling cascade via activa-
tion and autophosphorylation of IRb [19]. Once phosphory-
lated, the insulin receptor functions as a kinase which
phosphorylates proteins such as the insulin receptor substrate
(IRS) resulting in the downstream propagation of insulin sig-nal. Since previous studies have shown that chromium com-
plexes may enhance the number [18] and activity [20] of the
insulin receptors, subsequent experiments were performed to
study the eﬀect of Cr(pa)3 on insulin-stimulated IRb tyrosine
phosphorylation in 3T3-adipocytes. Treatment with insulin re-
sulted in a signiﬁcant increase in phosphorylation of IRb as ex-
pected, which was not altered by pretreating the cells with
Cr(pa)3 for various time or at diﬀerent concentrations (Figs.
2A and C). Neither did Cr(pa)3 alter IRb phosphorylation in-
duced by submaximal concentrations of insulin (1 nM) indicat-
ing that receptor saturation by the ligand may not be the
reason for the lack of eﬀect of Cr(pa)3 (ﬁgure not shown).
These results indicated that Cr(pa)3 may enhance insulin-stim-
ulated glucose-uptake via a mechanism(s) involving other than
at the site of insulin receptor.
3.4. Cr(pa)3 enhances insulin-induced phosphorylation of Akt
Akt has been identiﬁed as an important kinase, downstream
of insulin receptor necessary for insulin activity [21]. Treat-
ment of adipocytes with insulin resulted in an increase in
Akt (thr308) phosphorylation (Fig. 3). Pretreatment of adipo-
cytes with the chromium complex resulted in a further increase
in the insulin-stimulated Akt phosphorylation both in a con-
centration-dependent (Fig. 3A, upper panel) and time-depen-
dent manner (Fig. 3C, upper panel). Cr(pa)3 alone, in the
absence of insulin did not alter the phosphorylation levels of
Akt (data not shown). These results indicate that Cr(pa)3
may promote insulin signaling and glucose uptake by acting
at the post-receptor level.
3.5. Cr(pa)3 improves whole body glucose tolerance
Genetically obese, leptin deﬁcient C57BL/6J ob/ob(+/+) mice
and their lean controls were treated with Cr(pa)3 150 lg/kg/d,
for 6 weeks. Following acute glucose challenge, the ob/ob(+/+)
animals showed poor glucose tolerance compared to the lean
control mice as indicated by an increase in the area under
the post-treatment glucose concentration curve (Fig. 4A and
Fig. 3. Cr(pa)3 potentiates insulin-stimulated Akt (thr308) phosphorylation in 3T3-adipocytes. Cells were pretreated with Cr(pa)3 (5 lM) for
diﬀerent time period (panel A) or at diﬀerent concentrations for 2 h (panel C) followed by challenge with 10 nM of insulin for 10 min. Cells lysates
were subjected to SDS–PAGE and Western blotted against a phospho-Akt (thr308) antibody and reprobed with Akt antibody. Panel A:
representative Western blot for incubations with 5 lM Cr(pa)3 for diﬀerent time periods. Panel C: representative Western blot for incubations with
varying concentrations of Cr(pa)3 for 2 h; Panel B and D: ratios of gel optical densities of phosphorylated protein versus total protein for the time-
dependent and concentration-dependent experiments. Values are means ± S.E.M., n = 3. *P < 0.05 compared to insulin treatment in the absence of
Cr(pa)3.
Fig. 2. Cr(pa)3 does not alter insulin-stimulated phosphorylation of insulin receptor beta in 3T3-adipocytes. Cells were pretreated with Cr(pa)3
(5 lM) for diﬀerent times (A) or at diﬀerent concentrations for 2 h (C) followed by stimulation with 10 nM of insulin for 10 min. Cells lysates were
subjected to SDS–PAGE and Western blotted against a phospho-IGF-IR (Tyr1131)/Insulin receptor (Tyr1146) antibody (A, C upper panels) and
reprobed with antibody against insulin receptor beta (lower panels). Panels B and D gives the ratios of the respective optical densities of the
phosphorylated bands to that of the total protein. Values are means ± S.E.M., n = 3 or 4. Cr(pa)3 did not alter the phosphorylation of insulin
receptors at the concentrations and time tested.
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glucose levels following glucose challenge started to decline
after peaking at 15 min and returned to the baseline value after120 min (Fig. 4A). However, serum glucose levels in the
Cr(pa)3 treated ob/ob(+/+) mice were signiﬁcantly lower than
that of the untreated control animals at 15 and 60 min
Fig. 5. Generation of hydroxyl radicals by chromium complexes.
Panel A: the basal reaction mixture containing the test compounds
Cr(pa)3 or chromium picolinate (1.2 lM), 2-deoxyribose (4 mM),
ascorbic acid (100 lM) and hydrogen peroxide (100 lM) in potassium
phosphate buﬀer (pH 7.4, 10 mM) was incubated at 37 C for 30 min.
An aliquot of the mixture was treated with 1% (w/v) thiobarbituric
acid and 2.8% (w/v) trichloroacetic acid and heated at 90 C for
40 min, cooled and the amount of chromogen formed in the sample
was measured by its absorption at 532 nm. Ferric-EDTA (100 lM)
used as a positive control, generated hydroxyl radicals about 3.5-folds
over the reagent blank. Chromium picolinate showed a twofold
increase in hydroxyl radical production over control (*P < 0.05, n = 3)
as compared to reagent blank. There was no signiﬁcant diﬀerence
between Cr(pa)3 and the reagent blank. Panel B: eﬀects of chromium
picolinate and cr(pa)3 on ascorbate-stimulated cleavage of pUC19
DNA. The reactions (total volume 15 ll) contain pUC19 (38 lM in
base pairs) in phosphate buﬀer, pH 7.4 in the presence of ascorbate
and chromium complexes (1.2 lM). Reactions were allowed to proceed
for 60 min at room temperature before quenching. Chromium pico-
linate stimulated nicking of the DNA (conversion of supercoiled, faster
migrating DNA to circular slower migrating DNA) whereas Cr(pa)3
failed to induce DNA damage.
Fig. 4. Intraperitoneal glucose tolerance test (IPGTT) in ob/ob(+/+)
mice and lean controls before and after a 6-week treatment with
Cr(pa)3 (150 mg/kg/day). Cr(pa)3-treated group had a signiﬁcantly
higher rate of glucose disposal at 15, 60, and 120 min compared to
control animals. Panel A: time course curve of post-glucose-challenge
plasma glucose levels. Values are means ± S.E.M., *P < 0.005 (n = 10),
vs. vehicle-treated ob/ob(+/+) mice. Panel B: area under the plasma
glucose concentration curve (AUC) following IPGTT for obese and
lean mice treated with Cr(pa)3 or control. Cr(pa)3 treatment signiﬁ-
cantly reduced (*P < 0.005 versus untreated animals) the AUC for
glucose for obese mice but did not change the AUC in lean mice.
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120 min of glucose, shown in Fig. 4B, shows that the ob/
ob(+/+) mice receiving Cr(pa)3 has signiﬁcantly lower AUC
as compared to untreated animals. These eﬀects of Cr(pa)3
were found to be independent of the changes in the body
weight as there was no signiﬁcant diﬀerence in the body weight
of the ob/ob(+/+) animals treated with Cr(pa)3. Post-treatment
weights were 52.2 ± 1.6 g for treated versus 53.8 ± 2.6 g for un-
treated (P > 0.05 between the two groups, n = 10). Pre-treat-
ment weights were 28.2 ± 1.1 and 28.8 ± 1.0 g for treated and
untreated group, respectively. In contrast, in the lean mice,
there were no signiﬁcant changes in the AUC between the
Cr(pa)3-treated and untreated group.
3.6. Cr(pa)3 does not cleave DNA under physiologically relevant
conditions
Recent studies have indicated that the nutritional supple-
ment chromium picolinate can cause DNA damage by gener-
ating hydroxyl radicals [14]. The mutagenic potential of
chromium picolinate has been attributed by the picolinate li-
gand, which primes the redox potential of the chromic center
for reduction by biological reductants [22]. In contrast, the
phenylalanine ligand is known to scavenge hydroxyl radicals
via hydroxylation of the phenyl ring [23] which may be a po-tential strategy to avert the toxicity. The deoxyribose degrada-
tion assay was used to compare the pro-oxidant potential of
chromium picolinate and Cr(pa)3. Ferric-EDTA complex in
the presence of ascorbate generated hydroxyl radicals causing
signiﬁcant damage to deoxyribose (Fig. 5A). In this model sys-
tem, chromium picolinate induced a twofold increase (over
control) in hydroxyl radical production. In contrast, Cr(pa)3
failed to cause any degradation of deoxyribose, suggesting that
this compound may not generate hydroxyl radicals under the
conditions tested. The eﬀect of Cr(pa)3 on DNA damage was
monitored by observing the conversion of the supercoiled plas-
mid DNA to circular, nicked form (Fig. 5B). In accordance to
previous studies, in the presence of ascorbic acid, chromium
picolinate (1.2 lM) caused a nick in the pUC19 DNA. Inter-
estingly, equimolar concentrations of Cr(pa)3 under similar
conditions failed to induce any strand breaks in the DNA.
Insulin-stimulated phosphorylation of Akt is enhanced to a
greater extent by Cr(pa)3 as compared to that with chromium
picolinate. Fig. 6 shows that Cr(pa)3 induces greater stimula-
Fig. 6. Eﬀect of chromium picolinate and Cr(pa)3 on insulin-stimu-
lated Akt-phosphorylation in 3T3-adipocytes. Both the chromium
complexes enhanced the insulin-stimulated phosphorylation of Akt as
compared to control (ﬁgure A, upper panel). The enhancement was
more pronounced with Cr(pa)3 than with chromium picolinate. Figure
A lower panel is a blot for total Akt, a control for equal protein
loading. Panel B: ratios of gel optical densities of phosphorylated Akt
versus total protein. Values are means ± S.E.M., n = 3. *P < 0.05.
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chromium picolinate at equimolar concentrations.4. Discussion
This is the ﬁrst study to examine the eﬀect of a novel com-
plex of chromium with the amino acid D-phenylalanine on
insulin signaling and glucose tolerance. Major ﬁndings of
our study are (i) Cr(pa)3 enhances insulin-stimulated glucose
uptake in adipocytes, (ii) Cr(pa)3 improves insulin-signal trans-
duction in cultured mice adipocytes, (iii) oral feeding of
Cr(pa)3 to insulin resistant animals improves glucose tolerance
and (iv) Cr(pa)3 does not generate toxic hydroxyl radicals that
cleave DNA under physiological conditions.
The ability of chromium to enhance insulin-stimulated glu-
cose uptake in cultured cells has been reported previously
[18]. Though the exact mode of action of chromium is un-
known, several mechanisms have been proposed. Chromium
is thought to increase insulin binding to cells, to enhance the
insulin receptor number and to potentiate insulin receptor ki-
nase activity [20]. In our studies, however, Cr(pa)3 did not in-
crease the protein levels of insulin receptor nor did it enhance
the tyrosine phosphorylation of insulin receptor indicating that
chromium may be acting downstream of the insulin receptor.
Phosphorylation of Akt in response to insulin stimulation is
a pivotal event in insulin signal transduction that results in
the activation and translocation of glucose transporter
GLUT4-containing vesicles from the cytosol to plasma mem-
brane leading to cellular glucose uptake [24]. Besides its
involvement in the activation of GLUT4 vesicles, Akt can
phosphorylate glycogen synthase kinase 3, which is an essential
step in the activation of glycogen synthase, the enzyme in-
volved in glycogen synthesis. The present study indicates thatCr(pa)3 may be improving insulin sensitivity by enhancing
the insulin-stimulated phosphorylation of Akt. Interestingly,
a recently conducted clinical study demonstrates that individ-
uals with type-II diabetes who supplemented their diet with
chromium picolinate had increased activity of Akt (in the skel-
etal muscles) compared to those who were on placebo [25]. The
reported ability of wortmanin, a PI3-kinase inhibitor to inhibit
Cr-stimulated potentiation of insulin activity [26] underscores
Akt as a potential target for chromium compounds. Further-
more, the results presented here (Fig. 6) suggest that Cr(pa)3
may function as a more potent enhancer of insulin-stimulated
Akt phosphorylation than chromium picolinate. However, the
mechanism by which chromium enhances insulin-stimulated
Akt phosphorylation is unclear. One potential explanation
could be the inhibition of the enzyme phosphotyrosine phos-
phatase (PTP-1B) by chromium, which is a known negative
regulator of insulin signaling [27].
The identiﬁcation that chromium in the biologically active
form is a complex with a 1500 Da polypeptide leads to the syn-
thesis and evaluation of several low-molecular-weight organic
chromium complexes amongst which chromium picolinate has
been the most extensively studied compound [28]. One prob-
lem with chromium picolinate is its poor solubility in physio-
logical buﬀers that may result in poor bioavailability.
Besides, the picolinate ligand has been shown to generate hy-
droxyl radicals that can cause deleterious DNA damage
[10,14]. These observations prompted the use of a non-toxic
amino acid such as D-phenylalanine as the ligand to chelate
chromium. Phenylalanine besides having better solubility at
physiological pH is a known scavenger of hydroxyl radicals
[23]. Derivatives of D-phenylalanine such as nateglinide have
also shown to have beneﬁcial eﬀects in type II diabetes [29].
Thus, the rationale in synthesizing phenylalanine complex of
chromium was to obtain a better bioavailable, less toxic and
more eﬀective biomimetic complex of chromium. The present
study indicates that Cr(pa)3 possesses these attributes and
therefore would be an ideal candidate for further extensive
studies on its insulin-potentiating properties.5. Conclusion
This is the ﬁrst study to show that a novel synthetic complex
of chromium with the D-phenylalanine improves insulin
responsiveness and whole body glucose tolerance. Unlike chro-
mium picolinate, Cr(pa)3 does not cleave DNA under physio-
logical conditions. Taken together, it is tempting to speculate
that chromium complexes of amino acids may represent a no-
vel class of chromium complexes that is less toxic and poten-
tially beneﬁcial in the treatment and management of insulin
resistance and glucose intolerance in type II diabetes.
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